

| | | |
|--------------------------------|------------|-------------------|
| Freedom of Information Request | FOI 23-443 | 06 September 2023 |
|--------------------------------|------------|-------------------|

Your request

You requested the following:

- I am analysing the treatment of dermatological conditions in the UK. Could you please provide the number of patients treated in the last 4 months, by the dermatology department, with each of the following products:
 - Abrocitinib
 - Baricitinib
 - Dupilumab
 - Tralokinumab
 - Upadacitinib

Our response

- We are unable to provide information on the number of patients treated with specific drugs. However, please find in the table below the quantities dispensed across Health Board pharmacies for Dermatology only, for the period April 2023 – June 2023:

| Drug | Quantity |
|--|----------|
| ABROCITINIB 200 mg Tablets 28 Tablet Pack | 6 |
| DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack | 10 |
| DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack | 12 |
| DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Pen 2 Pre-Filled Pen Pack | 192 |
| DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack | 88 |
| TRALOKINUMAB (ADTRALZA) 150 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack | 18 |
| UPADACITINIB 15 mg Modified-Release Tablets 28 Tablet Pack | 4 |